U.S. IPO Weekly Recap: Keros Therapeutics Rises 35% As Biotechs Beat The IPO Shutdown [Seeking Alpha]
Keros Therapeutics, Inc. - common stock (KROS)
Company Research
Source: Seeking Alpha
SummaryKeros Therapeutics finished the week up 35%, affirming that the biotech industry won't be deterred by current market volatility.The IPO Index jumped 11.3% this past week, compared to a 10.4% increase for the S&P 500.The Vix Volatility Index settled to its lowest level in a month; if this trend continues, we could see IPO volume begin to normalize by summer.Another biotech IPO has beaten the market blues. Keros Therapeutics (NASDAQ:KROSOncology biotech Keros Therapeutics priced its upsized IPO at the high end to raise $96 million at a $325 million fully diluted market cap (+12% vs. original midpoint). The company priced its IPO at a 19% premium to its last capital raise in March 2020, and it believes its cash balance of $149 million will last into the 2H22. Keros' lead candidate, KER-050, is beginning a Phase 2 trial for anemia and thrombocytopenia associated with myelodysplastic syndromes (MDS). The company believes KER-050 will treat all stages of MDS, making it superior to cu
Show less
Read more
Impact Snapshot
Event Time:
KROS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KROS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KROS alerts
High impacting Keros Therapeutics, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
KROS
News
- Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 37%? [Yahoo! Finance]Yahoo! Finance
- Keros Therapeutics, Inc. (NASDAQ: KROS) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $105.00 price target on the stock.MarketBeat
- Morphic appoints Simon Cooper as CMO [Seeking Alpha]Seeking Alpha
- Morphic Appoints Dr. Simon Cooper as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Keros Therapeutics, Inc. (NASDAQ: KROS) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $100.00 price target on the stock.MarketBeat
KROS
Earnings
- 2/28/24 - Beat
KROS
Sec Filings
- 5/3/24 - Form S-3ASR
- 4/17/24 - Form ARS
- 4/17/24 - Form DEFA14A
- KROS's page on the SEC website